Based on these data, decreased serum PRL levels at ZT12 under SJL might inhibit hepatic CCND1 levels through MAPKs, leading to the activation of lipogenic enzymes (i.e., FASN and ACC) and hepatic steatosis. This evidence concerns the gene FASN and fatty liver disease.